RTP Mobile Logo
Prostate Cancer Update, Issue 2, 2021 (Video Program)
Released March 2021

Featuring perspectives from Prof Johann de Bono and Dr Charles J Ryan. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

    OVERVIEW OF ACTIVITY
    Cancers of the genitourinary system affect hundreds of thousands of individuals within the United States each year and comprise more than one fourth of all newly diagnosed human cancer cases. Of this diverse array of distinct diseases, tumors of the prostate are among the most prevalent and thus the focus of extensive ongoing clinical research. A result of this research is that the clinical management of both early and more advanced presentations of prostate cancer is constantly evolving, necessitating rapid and consistent access to learning opportunities for clinicians.

    To provide clinicians with therapeutic strategies to address the needs of patients with prostate cancer, this program, developed in partnership with the University of South Florida (USF Health) Office of Continuing Professional Development, features presentations and one-on-one discussions with leading clinical investigators. By providing expert perspectives on the latest developments, this activity will assist medical oncologists with the formulation of evidence-based and current therapeutic strategies, which in turn will facilitate optimal patient care.

    LEARNING OBJECTIVES

    • Appraise the published research database supporting approved and investigational secondary hormonal agents in the management of nonmetastatic prostate cancer, and consider this information in the discussion of treatment options for patients.
    • Recall available data on the use of cytotoxic and secondary hormonal therapy in the setting of metastatic hormone-sensitive prostate cancer to design effective treatment plans for patients.
    • Recognize how prior therapeutic exposure and other patient and disease characteristics factor into the selection and sequencing of available systemic treatments for metastatic castration-resistant prostate cancer (CRPC).
    • Understand the rationale for testing patients with metastatic prostate cancer for DNA damage repair alterations, including BRCA1/2 mutations, and advise individuals found to harbor these genetic abnormalities about the availability of PARP inhibitor-based therapies in or outside of a clinical trial setting.
    • Recall the design of ongoing research studies evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.
    • Educate patients about the side effects associated with approved therapies commonly employed in the management of advanced prostate cancer, and provide preventive strategies to reduce or ameliorate these toxicities.

    CONTACT INFORMATION
    If you have questions regarding credit, please contact cpdsupport@usf.edu.

    ACCREDITATION STATEMENT
    USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Audio Program: USF Health designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: USF Health designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components, enables the participant to earn up to 3.25 (audio) and 3.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    For ABIM MOC points, your information will be shared with the ABIM through USF Health's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for MOC points to appear on your ABIM records.

    Personal information and data sharing: Research To Practice and USF Health aggregate deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide sets, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ProstateCancerUpdate221/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ProstateCancerUpdate221/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ProstateCancerUpdate221/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ProstateCancerUpdate221.

    CONTENT VALIDATION AND DISCLOSURES
    USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Johann de Bono, MBChB, MSc, PhD
    Regius Professor of Cancer Research
    The Institute of Cancer Research, University of London
    The Royal Marsden Hospital
    London, United Kingdom

    Advisory Committee, Consulting Agreements and Data and Safety Monitoring Board/Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, CellCentric, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, Janssen Biotech Inc, Merck Serono, Merck Sharp & Dohme Corp, Menarini Silicon Biosystems, Orion Corporation (Finland), Pfizer Inc, QIAGEN, Sanofi Genzyme, Sierra Oncology, Taiho Oncology Inc, Terumo Medical Corporation, Vertex Pharmaceuticals; Contracted Research (Institution – no personal income): Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CellCentric, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, Janssen Biotech Inc, Merck Serono, Merck Sharp & Dohme Corp, Menarini Silicon Biosystems, Orion Corporation, Pfizer Inc, Sanofi Genzyme, Sierra Oncology, Taiho Oncology Inc, Vertex Pharmaceuticals; Ownership Interest: Inventor, with no financial interest, for patent 8,822,438.

    Charles J Ryan, MD
    Professor of Medicine
    BJ Kennedy Chair in Clinical Medical Oncology
    Director, Division of Hematology, Oncology and Transplantation
    University of Minnesota
    Minneapolis, Minnesota

    No financial interests or affiliations to disclose.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    USF HEALTH CPD STAFF AND RESEARCH TO PRACTICE CME PLANNING COMMITTEE — Members, Staff, and Reviewers have no relevant conflicts to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. USF Health and Research To Practice do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Merck, and Sanofi Genzyme.

    Release date: March 2021
    Expiration date: March 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Presentation and Interview with
Charles J Ryan, MD

Presentation and Interview with
Johann de Bono, MBChB, MSc, PhD

Select Publications